
Healthcare · BSE
Aptus Pharma Ltd, incorporated in 2010, is engaged in the marketing and distribution of finished pharmaceutical formulations. The company manufactures and distributes a wide range of products across multiple therapeutic areas including antacids and PPIs, pain management, anti-inflammatories, antibiotics, cardiology and antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, and sachets. Its business divisions include Aptus Pharma, which focuses on acute therapies such as anti-infectives and pain management; Aptus CD Care, which specializes in chronic therapies; Aptus Wellcare, which offers wellness and nutraceutical products; and Aptus Global, which caters to the export market. As of March 31, 2025, the company had developed 194 pharmaceutical formulations across more than eleven therapeutic segments. It operates warehouses covering 15,732 sq. feet and 1,989 sq. feet in Ahmedabad, Gujarat. The company’s distribution network consists of 125 direct and sub-distributors supported by a sales team of 54 field personnel, and it employed 70 people as of March 31, 2025.
Price Band
₹65 – ₹70
Issue Size
₹13.02 Cr
Lot Size
2000 shares
GMP
+5.7%
Est. Listing
₹74
at current GMP
Subscribed
21.48x
overall
Open
23 Sep 2025
Close
25 Sep 2025
Allotment
26 Sep 2025
Refund
27 Sep 2025
Demat Credit
28 Sep 2025
Listing
30 Sep 2025
Last updated: 19 Oct 2026
Current Premium
Issue Price (Upper)
₹70
Band: ₹65 – ₹70
Estimated Listing Price
₹74
Upper price + GMP
Lot Size
2000 shares
Min investment ₹1,40,000
Estimated Profit / Lot
₹8,000
2000 × ₹4
Grey Market Premium trend
+₹4
▲ 0 today
Updated less than a minute ago
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 31 Oct 2026 | +₹4 | 5.7% | ₹74 |
| 30 Oct 2026 | +₹4 | 5.7% | ₹74 |
| 29 Oct 2026 | +₹4 | 5.1% | ₹74 |
GMP is unofficial market data. Not a guarantee of listing performance.
Aptus Pharma Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹13.02 Crores. The shares are offered at a price band of ₹65 to ₹70 per equity share on BSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 2000 shares (approx. ₹1,40,000 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Bigshare Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2025-09-28, while un-allotted funds or UPI block mandates will be released on 2025-09-27.
The latest grey market premium for Aptus Pharma Limited IPO is ₹4, which indicates an expected listing price of ₹74.
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.